Department of Biochemistry, University of Missouri, Columbia, Missouri 65211, United States.
Department of Chemistry, University of Missouri, Columbia, Missouri 65211, United States.
ACS Chem Biol. 2021 Nov 19;16(11):2268-2279. doi: 10.1021/acschembio.1c00427. Epub 2021 Sep 20.
Proline dehydrogenase (PRODH) is a flavoenzyme that catalyzes the first step of proline catabolism, the oxidation of l-proline to Δ-pyrroline-5-carboxylate. PRODH has emerged as a cancer therapy target because of its involvement in the metabolic reprogramming of cancer cells. Here, we report the discovery of a new class of PRODH inactivator, which covalently and irreversibly modifies the FAD in a light-dependent manner. Two examples, 1,3-dithiolane-2-carboxylate and tetrahydrothiophene-2-carboxylate, have been characterized using X-ray crystallography (1.52-1.85 Å resolution), absorbance spectroscopy, and enzyme kinetics. The structures reveal that in the dark, these compounds function as classical reversible, proline analogue inhibitors. However, exposure of enzyme-inhibitor cocrystals to bright white light induces decarboxylation of the inhibitor and covalent attachment of the residual S-heterocycle to the FAD N5 atom, locking the cofactor into a reduced, inactive state. Spectroscopic measurements of the inactivation process in solution confirm the requirement for light and show that blue light is preferred. Enzyme activity assays show that the rate of inactivation is enhanced by light and that the inactivation is irreversible. We also demonstrate the photosensitivity of cancer cells to one of these compounds. A possible mechanism is proposed involving photoexcitation of the FAD, while the inhibitor is noncovalently bound in the active site, followed by electron transfer, decarboxylation, and radical combination steps. Our results could lead to the development of photopharmacological drugs targeting PRODH.
脯氨酸脱氢酶(PRODH)是一种黄素酶,可催化脯氨酸分解代谢的第一步,即将 l-脯氨酸氧化为Δ-吡咯啉-5-羧酸。由于 PRODH 参与癌细胞的代谢重编程,因此它已成为癌症治疗的靶标。在这里,我们报告了一种新的 PRODH 失活剂的发现,该失活剂以光依赖性的方式使 FAD 发生共价和不可逆修饰。使用 X 射线晶体学(1.52-1.85Å分辨率)、吸收光谱和酶动力学对两个实例,1,3-二硫杂环戊烷-2-羧酸酯和四氢噻吩-2-羧酸酯进行了表征。结构表明,在黑暗中,这些化合物作为经典的可逆脯氨酸类似物抑制剂起作用。然而,将酶-抑制剂共晶体暴露于明亮的白光下会诱导抑制剂脱羧,并将残留的 S-杂环共价连接到 FAD N5 原子上,从而将辅因子锁定在还原的非活性状态。溶液中失活过程的光谱测量证实了光的要求,并表明蓝光是首选。酶活性测定表明,光增强了失活的速率,并且失活是不可逆的。我们还证明了这些化合物之一对癌细胞的光敏性。提出了一种可能的机制,涉及 FAD 的光激发,而抑制剂在活性部位非共价结合,随后是电子转移、脱羧和自由基结合步骤。我们的结果可能导致针对 PRODH 的光药理学药物的开发。